The Only Real Number in This Whole Debate Is 42 to 61 Percent, and It’s Not About You
I like numbers because they either hold up or they don’t. So when I went looking at what’s floating around for Thymosin Beta-4 dosing, injection amounts, “loading phases,” weekly milligram totals stated to the decimal, I did what I do with any dataset handed to me: I asked where it came from. The answer, once you trace it back, is nowhere. Not “nowhere reputable.” Nowhere. There is no human dose-finding trial for injectable Thymosin Beta-4 in healthy people recovering from injury. Zero. That’s not my opinion, that’s the state of the published literature.
So this isn’t going to be a dosing guide. It’s going to be an audit of the numbers you’ll actually be shown, and a look at the one number in this whole file that’s real.
The evidence ledger: five studies, zero that answer your question
Here’s how I’d lay out every piece of research anyone cites when they talk about this compound. I built this as a table because a table is the fastest way to see what a wall of text tries to hide.
| Study (year) | Species | Route | What it measured | Answers “how much should I inject for recovery”? |
|---|---|---|---|---|
| Malinda et al., 1999[^c1] | Rat | Topical, wound | Reepithelialization speed | No |
| Bock-Marquette et al., Nature, 2004[^c2] | Mouse | Injected, post-simulated heart attack | Cardiac cell survival/function | No (wrong species, wrong condition) |
| Tokura et al., 2011[^c3] | Cell culture | N/A | Muscle-precursor cell migration | No (mechanism only) |
| Guarnera et al., 2007[^c4] | Human | Topical gel | Venous leg ulcer healing | No (wrong route) |
| Sosne et al., Cornea, 2015[^c5] | Human | Eye drops | Dry eye symptoms and corneal staining | No (wrong route, wrong target) |
Five studies. Two species, four routes, zero that involve injecting the peptide into a healthy human for muscle or tendon recovery. That’s the honest count. Everything else you read online is built on top of this table, not inside it.
The one number that’s actually real
If you want a genuine figure to hold onto, it’s this: in the 1999 rat study, reepithelialization improved roughly 42 to 61 percent versus saline.[^c1] That’s a real range, from a real experiment, with a real control group. I’d trust it as far as it goes.
It just doesn’t go very far. It’s a rat, it’s a topical wound, and it’s a percentage improvement in skin closure, not a milligram figure, not an injection, and not a human. If someone shows you a dosing chart and tells you it’s “based on the research,” ask them which research, and then ask them to explain how a rat’s healed cut becomes your weekly syringe amount. There’s no conversion table for that, because nobody has built one. Nobody could, without running the trial.
Reading a dosing chart like you’d read a suspicious spreadsheet
I look at data for a living, and the tell I watch for is false precision, numbers reported with more confidence than the underlying method supports. Apply that here and the charts fall apart fast.
A weekly dose listed to two decimal places, for a compound with zero human dose-finding trials, isn’t precision. It’s decoration. Real clinical dosing ranges come from measuring outcomes across groups of people and finding where benefit outweighs risk. Nobody did that math for injectable Thymosin Beta-4, so any chart claiming an exact number is reporting a guess dressed as a finding.
The “loading phase, then maintenance phase” structure you’ll see everywhere is the same problem in a different outfit. It sounds like something out of a pharmacology textbook. It isn’t drawn from one, because the trial that would generate it doesn’t exist. It’s a convention, copied enough times that it now looks like consensus.
There’s also a substitution problem worth flagging with its own line item: a lot of what’s sold online as “Thymosin Beta-4” is actually TB-500, a cheaper synthetic fragment of the same molecule. The research base I laid out in the table above is almost entirely on the full peptide. If a seller cites that research while shipping you TB-500, you’re looking at a chart built for compound A being applied to compound B. That’s not a rounding error, that’s a different molecule.
The caveat: dose isn’t even the variable that matters most
Here’s where I’d push back on the whole framing of “what’s the right dose.” For an unapproved compound, dose is not the biggest risk factor. Two other variables dwarf it:
What’s actually in the vial. A product labeled “research use only, not for human consumption” carries no guarantee of purity, identity, or sterility, because that label exists specifically to exempt it from the standards that would guarantee those things. A seller’s own certificate of analysis is better than nothing, but it’s the seller grading its own homework, often without a batch number tied to what’s in your hand.
Whether anyone qualified looked at you first. No dosing chart asks about your medications, your history, or whether this is a reasonable idea for your specific situation. A chart can’t screen you. A person can.
The pick
If I’m ranking the ways to approach this, the supervised route wins by a wide margin, and not because the science gets stronger there. It doesn’t. The trial gap stays exactly as wide either way. What changes is the two variables above: a telehealth provider working through a licensed pharmacy, FormBlends being the one I’d point to, has a licensed clinician review your history before anything is prescribed, and a licensed compounding pharmacy preparing a known-quantity product rather than a mystery vial from a research-chemical site. Nobody is selling you anything here, and there’s no checkout link in this article, just a description of which path replaces unknowns with knowns.
That structure also happens to be the one place where a number is worth recording rather than copying. FormBlends runs a tracker app for logging each dose and check-in alongside a clinician-set protocol. A number you logged yourself, tied to how you actually felt, beats a number you copied off a forum thread every single time. It’s the difference between data and folklore.
The non-negotiables regardless of what you decide
A few facts don’t move no matter which chart you’re looking at. This compound isn’t FDA-approved, so there’s no approved product with a validated label dose. Anything legitimate runs through compounding under a prescription, and the rules governing that have been shifting through 2024 into 2026, so check the FDA’s own bulk-substances page rather than taking a vendor’s word for the current status.[^c1-fda]
And if you’re a tested athlete, the numbers argument is moot before it starts. Thymosin Beta-4 and TB-500 sit under WADA’s Prohibited List, Section S2, prohibited at all times.[^c2-wada] The issue there is eligibility and detection, not milligrams. Call your federation, not a sales rep.
What readers ask most
Is there an official dose for injectable Thymosin Beta-4? No. Zero human dose-finding trials exist for this use, which means every milligram figure circulating online traces back to convention and repetition rather than measured outcomes.
Why do the vendor charts get so specific, down to the decimal? Because specificity reads as authority. It’s the opposite of what real dosing evidence looks like: the more precise the number, the less likely it’s backed by an actual trial for this compound and this use.
Do the two human trials tell me anything about an injection dose? Not for this purpose. One was a topical gel on venous leg ulcers,[^c4] the other was an eye drop for dry eye.[^c5] Different route, different condition, different everything. Citing them to justify an injection amount is borrowing credibility they don’t carry.
Is TB-500 just Thymosin Beta-4 under another name? No, it’s a synthetic fragment, and cheaper to produce. Most of the cited research sits on the full peptide. A chart citing that research while selling TB-500 is applying one molecule’s evidence to a different molecule.
If not dose, what actually determines the risk here? What’s in the vial, and whether a clinician screened you before you used it. Those two variables outweigh the milligram question by a wide margin for any unapproved compound.
Can a tested athlete use this at any dose? No. WADA lists both Thymosin Beta-4 and TB-500 under Section S2, prohibited at all times, regardless of amount.[^c2-wada]
Quick reference: what this molecule is, in plain figures
What does it actually do in cells? It’s a small peptide that regulates actin, the protein scaffolding that lets cells move. That migration role is why researchers keep circling back to it for wound healing and tissue repair, though most of that interest still sits in animal models and small early-phase trials rather than confirmed human treatment protocols.
Does the underlying science hold up? Partially, and that’s the honest split. The animal data on corneal healing and cardiac repair is fairly consistent across studies. The human trials that exist are small and narrow in scope. It’s doing something real at the cell level, so it isn’t pure noise, but calling it a validated treatment for any specific condition overstates what five studies can support.
Is it legal to buy? It depends entirely on the route. It isn’t FDA-approved as a finished drug, so it can’t legally be marketed that way in the US. It can be compounded by a licensed pharmacy under a prescription for a specific patient, which is the accountable path, sometimes run through physician-supervised providers like FormBlends. Buying it as a labeled research chemical sits in much murkier territory.
What side effects show up in the human data? Mostly mild: injection-site reactions, some fatigue, occasional headache. No consistent pattern of serious events in what’s published, but those trials were small and short, so that reassurance has a low ceiling. No long-term safety study exists, which is its own kind of data gap.
References
[^c1]: Malinda KM, Sidhu GS, Mani H, et al. “Thymosin beta4 accelerates wound healing.” Journal of Investigative Dermatology. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/ [^c2]: Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.” Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/ [^c3]: Tokura Y, Nakayama Y, Fukada S, et al. “Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts.” Journal of Biochemistry. 2011;149(1):43-48. [^c4]: Guarnera G, De Rosa A, Camerini R. “Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing.” Annals of the New York Academy of Sciences. 2007;1112:407-412. [^c5]: Sosne G, Dunn SP, Kim C. “Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.” Cornea. 2015;34(5):491-496. [^c1-fda]: U.S. Food and Drug Administration. “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.” [^c2-wada]: World Anti-Doping Agency. “The Prohibited List.” Section S2, prohibited at all times.
